Onena Medicines

Description: Onena Medicines develops AI-driven antibody therapies targeting DSIPs to treat metastatic cancers & rare diseases, with lead candidate OMED-101 showing preclinical efficacy.

Country: Spain

Based in: Pais Vasco

Founded: 2019

Funding Stage: Series A/B

Tags: ['Biotechnology', 'Health Care', 'Medical Device']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.